BioCryst to Report Second Quarter 2024 Financial Results on August 5

Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq: BCRX) has announced that it will release its second quarter 2024 financial results on Monday, August 5, 2024. The company's management team will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the financial results and provide a corporate update. Interested parties can access the live call by dialing 1-844-481-2942 (domestic) or 1-412-317-1866 (international). Additionally, a live webcast and replay of the call will be available in the investors section of the company's website at www.biocryst.com.

News Market Reaction – BCRX

+3.92%

+3.92% Session move

In the trading session that priced this news, BCRX gained 3.92%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2024 financial results on Monday, August 5, 2024.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO^® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

FAQ

When will BioCryst Pharmaceuticals (BCRX) report its Q2 2024 financial results?

BioCryst Pharmaceuticals (BCRX) will report its second quarter 2024 financial results on Monday, August 5, 2024.

What time is BioCryst's (BCRX) Q2 2024 earnings call scheduled for?

BioCryst's (BCRX) Q2 2024 earnings call is scheduled for 8:30 a.m. ET on Monday, August 5, 2024.

How can investors access BioCryst's (BCRX) Q2 2024 earnings call?

Investors can access BioCryst's (BCRX) Q2 2024 earnings call by dialing 1-844-481-2942 for domestic callers or 1-412-317-1866 for international callers. A live webcast will also be available on the company's website.

Where can I find the replay of BioCryst's (BCRX) Q2 2024 earnings call?

The replay of BioCryst's (BCRX) Q2 2024 earnings call will be available in the investors section of the company's website at www.biocryst.com.